The anti-PD-1 era - an opportunity to enhance radiotherapy for patients with bladder cancer.
AffiliationTargeted Therapy Group, Division of Cancer Sciences, School of Medical Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester Academic Health Sciences Centre, 555 Wilmslow Road, Withington, Manchester M20 4BX
MetadataShow full item record
AbstractAn urgent need exists to improve the outcomes of patients with muscle-invasive bladder cancer (MIBC), and especially of those with metastatic disease. Treatments that enhance antitumour immune responses - such as immune-checkpoint inhibition - provide an opportunity to do this. Despite initial success, durable response rates in patients with advanced-stage MIBC treated with novel inhibitory antibodies targeting programmed cell death protein 1 (PD-1) or its endogenous ligand programmed cell death 1 ligand 1 (PD-L1) remain low. Radiotherapy is part of the management of bladder cancer in many patients. Evidence that radiotherapy has immunogenic properties is now available, but radiotherapy-induced immune responses are often negated by immunosuppression within the tumour microenvironment. Anti-PD-1 or anti-PD-L1 antibodies might enhance radiotherapy-induced antitumour immunity. This effect has been demonstrated in preclinical models of bladder cancer, and clinical trials involving this approach are currently recruiting. Combination treatment strategies provide an exciting opportunity for urological oncologists to not only improve the chances of cure in patients undergoing radical treatment for MIBC, but also to increase long-term response rates in those with metastatic disease.
CitationThe anti-PD-1 era - an opportunity to enhance radiotherapy for patients with bladder cancer. 2017 Nat Rev Urol
JournalNature Reviews Urology
DescriptionLymphoma Research Team
- Immune Checkpoint Inhibitors in Lung Cancer - An Unheralded Opportunity?
- Authors: Marshall R, Popple A, Kordbacheh T, Honeychurch J, Faivre-Finn C, Illidge T
- Issue date: 2017 Apr
- A Systematic Review of Immunotherapy in Urologic Cancer: Evolving Roles for Targeting of CTLA-4, PD-1/PD-L1, and HLA-G.
- Authors: Carosella ED, Ploussard G, LeMaoult J, Desgrandchamps F
- Issue date: 2015 Aug
- Immuno-regulatory antibodies for the treatment of cancer.
- Authors: Honeychurch J, Cheadle EJ, Dovedi SJ, Illidge TM
- Issue date: 2015 Jun
- Correlation between messenger RNA expression and protein expression of immune checkpoint-associated molecules in bladder urothelial carcinoma: A retrospective study.
- Authors: Le Goux C, Damotte D, Vacher S, Sibony M, Delongchamps NB, Schnitzler A, Terris B, Zerbib M, Bieche I, Pignot G
- Issue date: 2017 May
- Emerging role of immunotherapy in urothelial carcinoma-Immunobiology/biomarkers.
- Authors: Sweis RF, Galsky MD
- Issue date: 2016 Dec